Socioeconomic Impact of OncotypeDX on Breast Cancer Treatment: Preliminary Results

background/aim: breast cancer (BC) is the most prevalent oncological diagnosis worldwide. molecular subtyping has provided valuable insights for treatment decisions, but challenges remain in adjuvant treatment for hormone receptor (HR)-positive/HER2-negative luminal BC (LBC). multigene markers like oncotype DX have emerged to provide more precise prognostic information. this study aimed to evaluate the influence of gene expression panels on fear of cancer recurrence (FCR), quality of life (QoL), and healthcare-related greenhouse emissions. patients and methods: a monocentric retrospective analysis was conducted using a prospective database of patients undergoing oncotype DX. QoL assessments were performed using the short breast health perception questionnaire (BHPQ) and life satisfaction questionnaire (LSQ-32). reductions in hospital visits and travel distance were analyzed. results: twenty-eight patients underwent oncotype DX testing. of these, 17.85% received adjuvant chemotherapy based on the recurrence score (RS). the implementation of oncotype DX resulted in a significant reduction in hospital visits, travel distance, and healthcare-related greenhouse gas emissions. QoL assessments using BHPQ and LSQ-32 showed lower levels of FCR and improved QoL in various domains for patients who received hormone therapy (HT) alone. conclusion: the implementation of oncotype DX in clinical practice has the potential to reduce overtreatment, decrease healthcare-related greenhouse gas emissions, and improve QoL. lower levels of FCR and improved QoL were observed in patients who received HT-only based on the RS score.